Today: 30 June 2026
Synopsys stock slips premarket after HSBC downgrade as SNPS heads into earnings week
23 February 2026
1 min read

Synopsys stock slips premarket after HSBC downgrade as SNPS heads into earnings week

New York, February 23, 2026, 06:18 EST — Premarket

  • Synopsys edged down about 0.6% before the bell, giving back some ground after Friday’s close.
  • HSBC cut Synopsys to “hold” and lowered the price target.
  • Synopsys will release its results and outlook on Feb. 25, leaving investors uneasy.

Synopsys shares edged down about 0.6% to $437.50 in U.S. premarket trading Monday, after closing at $439.94 on Friday. The decline came as HSBC cut its rating on the chip-design software maker, just ahead of the company’s upcoming quarterly report.

Fresh tariff chatter has rattled risk appetite, pulling U.S. stock index futures lower before the bell. “It’s really hard … to know how do you plan,” said Arthur Laffer Jr., president of Laffer Tengler Investments, pointing to the uncertainty tariffs inject into corporate planning. Reuters

Synopsys investors have a date to circle: the company’s first-quarter fiscal 2026 numbers drop after the bell on Wednesday, Feb. 25. Execs are set to walk through guidance starting at 5 p.m. Eastern on the conference call.

HSBC Global Investment Research cut Synopsys to “hold” from “buy” on Friday, flagging a scarce catalyst pipeline through full-year 2026 and noting increasing headwinds across the company’s core businesses. Analysts at the bank slashed their price target to $455, down from $545, citing weaker momentum in Design IP — the standard chip blocks Synopsys licenses out. Pressure is also showing up in electronic design automation (EDA), HSBC said, as the company faces geopolitical risk, stiffer China export controls, and questions swirling around Intel’s foundry strategy. Investing.com

Cadence Design Systems was caught in the downdraft as well, off about 0.4% at $294.99 before the bell. The chip design tools giant remains a core name in the sector.

Synopsys is often watched as a bellwether for demand tied to high-end processors—particularly those used in artificial intelligence. When the company shifts its outlook, investors usually read it as a cue to customer spending patterns and take it as an indicator for the wider semiconductor tools sector.

But the downgrade isn’t the end of the story. If Wednesday’s outlook beats forecasts, that might help soften the blow. Any sign of weaker demand, though, could keep shares on the back foot.

Investor money has started shifting into high-priced tech stocks after the latest tariff headlines. That’s proving key for names like Synopsys, where sentiment whipsaws, regardless of whether there’s any new company news.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Conagra Brands (CAG) Dividend Yield Tops 10% as Shares Fall
    June 29, 2026, 5:56 PM EDT. Conagra Brands Inc (CAG) stock briefly offered a yield above 10% Monday after the shares fell to $13.88. The yield uses the quarterly dividend, annualized at $1.40. Dividends make up a big part of investor returns, and historical numbers show payouts add to gains even when shares move around. Conagra is a major S&P 500 name with a high yield, but that payout could change depending on the company's profits. Investors may want to review Conagra's dividend track record to judge if this level is likely to hold.
Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares
Previous Story

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop